Does Censavudine / TPN-101 (LINE-1 suppression) work?

Read Off Label rates the evidence for Censavudine / TPN-101 (LINE-1 suppression) as Preclinical for aging and the benefit magnitude as med, producing an overall grade of D+ (3.7/10). Transposon Therapeutics.

Is Censavudine / TPN-101 (LINE-1 suppression) safe?

Censavudine / TPN-101 (LINE-1 suppression) has a med risk profile in published human data. Legal status: Investigational (repurposing; ARPA-H PROSPR-funded). This is not medical advice — see the disclaimer.

Rankings / Longevity — Supplements

Censavudine / TPN-101 (LINE-1 suppression)

Longevity · Reverse transcriptase inhibitor (NRTTI)

Tier D+

Reviewed by Read Off Label · Last reviewed Jun 7, 2026 · How we grade

retrotransposonline-1inflammagingreverse-transcriptaserepurposingfrontierinvestigationalpreclinical

3.7 / 10

Tier D+

Ev 2 Bn 5 Sf 5

Bottom line

Read Off Label grades Censavudine / TPN-101 (LINE-1 suppression) as D+ (3.7/10) based on preclinical for aging evidence, med benefit magnitude, and a med-risk safety profile.

Transposon Therapeutics.

Typical use: Oral; doses from prior neurology trials — Investigational.

What this is

Transposon Therapeutics. ARPA-H PROSPR award (up to $22M) funds a ~200-participant 48-week trial in healthy adults aged 60-65 testing whether suppressing LINE-1 retrotransposons improves mobility, cognition and vitality (the Gorbunova/Sedivy inflammaging hypothesis). Existing safety from PSP/ALS-FTD Phase 2 trials de-risks the repurposing; no aging-specific human readout yet. Frontier. Grant/industry-sponsored.

Mechanism

Nucleoside reverse-transcriptase translocation inhibitor (originally an HIV drug) repurposed to suppress LINE-1 retrotransposon activity; reactivated transposable elements are an emerging driver of inflammaging and genomic instability.

Dose & route

Oral; doses from prior neurology trials

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Censavudine / TPN-101 (LINE-1 suppression) work?: Read Off Label rates the evidence for Censavudine / TPN-101 (LINE-1 suppression) as Preclinical for aging and the benefit magnitude as med, producing an overall grade of D+ (3.7/10). Transposon Therapeutics.
Is Censavudine / TPN-101 (LINE-1 suppression) safe?: Censavudine / TPN-101 (LINE-1 suppression) has a med risk profile in published human data. Legal status: Investigational (repurposing; ARPA-H PROSPR-funded). This is not medical advice — see the disclaimer.
What is the typical dose for Censavudine / TPN-101 (LINE-1 suppression)?: Oral; doses from prior neurology trials
How does Censavudine / TPN-101 (LINE-1 suppression) work?: Nucleoside reverse-transcriptase translocation inhibitor (originally an HIV drug) repurposed to suppress LINE-1 retrotransposon activity; reactivated transposable elements are an emerging driver of inflammaging and genomic instability.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.